Search

We reviewed Giemsa-stained thick blood smears, obtained through the national malaria surveillance program in the Amazon region of Ecuador, by light microscopy for Mansonella spp. microfilariae. Of 2,756 slides examined, 566 (20.5%) were positive. Nested PCR confirmed that the microfilariae were those of M. ozzardi nematodes, indicating that this parasite is endemic to this region.

Objective: Emergence and dissemination of colistin-resistant (Co-R) bacteria harboring mobile colistin resistance genes pose a threat for treatment of infections caused by multi-drug resistant bacteria. Although the worldwide spread of Co-R bacteria is known, the precise state of Co-R bacterial dissemination in livestock of Andean countries remains unclear. Therefore, we investigated mcr-containing Co-R Escherichia coli dissemination in livestock on small-scale farms in two socioecologically different regions of Ecuador: the Amazonian rain-forest and the Pacific Coast., Results: Sixty-six rectal swab samples from 34 pigs and 32 chickens, from five farms in the two regions, were assessed for the dissemination of Co-R E. coli using the selective medium CHROMagar™ COL-APSE. mcr-containing Co-R E. coli were detected in the specimens at a high rate (47%; 31/66), but the detection rates of the two regions were not statistically different. Both chickens and pigs showed similar detection rates. All Co-R E. coli isolates harbored mcr-1. The minimum inhibitory concentrations of colistin were ≥ 8 mg/L, and 67.7% (21/31) of the Co-R isolates were multi-drug resistant. Pulsed-field gel electrophoresis revealed the limited relation between isolates. Thus, we revealed the high rate of widespread dissemination of Co-R bacteria in livestock regardless of the socioecological conditions in Ecuador.

Importance: Abnormal peripheral perfusion after septic shock resuscitation has been associated with organ dysfunction and mortality. The potential role of the clinical assessment of peripheral perfusion as a target during resuscitation in early septic shock has not been established., Objective: To determine if a peripheral perfusion-targeted resuscitation during early septic shock in adults is more effective than a lactate level-targeted resuscitation for reducing mortality., Design, Setting, and Participants: Multicenter, randomized trial conducted at 28 intensive care units in 5 countries. Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018. The last date of follow-up was June 12, 2018., Interventions: Patients were randomized to a step-by-step resuscitation protocol aimed at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period., Main Outcomes and Measures: The primary outcome was all-cause mortality at 28 days. Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay., Results: Among 424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06; risk difference, -8.5% [95% CI, -18.2% to 1.2%]). Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00 [95% CI, -1.97 to -0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes. No protocol-related serious adverse reactions were confirmed., Conclusions and Relevance: Among patients with septic shock, a resuscitation strategy targeting normalization of capillary refill time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality., Trial Registration: ClinicalTrials.gov Identifier: NCT03078712.